DermTech Company Leadership
| DMTK Stock | USD 0.62 0.04 6.06% |
DermTech's insiders are aggressively selling. The analysis of the overall insider sentiment regarding DermTech suggests that most insiders are panicking. DermTech employs about 206 people. The company is managed by 17 executives with a total tenure of roughly 481 years, averaging almost 28.0 years of service per executive, having 12.12 employees per reported executive.
DermTech's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2023-12-11 | Claudia Ibarra | Disposed 331 @ 1.45 | View | ||
| 2023-12-07 | Ramin Akhavan | Disposed 3768 @ 1.53 | View | ||
| 2023-09-11 | Kevin M Sun | Disposed 436 @ 1.89 | View | ||
| 2023-09-08 | Claudia Ibarra | Disposed 7378 @ 1.93 | View | ||
| 2023-06-12 | Claudia Ibarra | Disposed 322 @ 2.85 | View | ||
| 2023-06-07 | Todd Michael Wood | Disposed 4992 @ 2.53 | View |
Monitoring DermTech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
DermTech |
DermTech Management Team Effectiveness
The company has return on total asset (ROA) of (0.3782) % which means that it has lost $0.3782 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0646) %, meaning that it created substantial loss on money invested by shareholders. DermTech's management efficiency ratios could be used to measure how well DermTech manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.87. The value of Return On Capital Employed is expected to slide to -1. At this time, DermTech's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 53.9 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 82 M.Common Stock Shares Outstanding is expected to rise to about 34.3 M this year, although the value of Net Loss is projected to rise to (99.8 M).
DermTech Workforce Comparison
DermTech is rated # 3 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 2,609. DermTech holds roughly 206 in number of employees claiming about 8% of equities under Health Care industry.
DermTech Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DermTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on DermTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DermTech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Todd Wood over two weeks ago Acquisition by Todd Wood of 85114 shares of DermTech subject to Rule 16b-3 | ||
Sun Kevin M over a month ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.7 subject to Rule 16b-3 | ||
Sun Kevin M over a month ago Disposition of 2531 shares by Sun Kevin M of DermTech at 0.88 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Sale by Sun Kevin M of 223 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 514 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 198 shares of DermTech |
DermTech Notable Stakeholders
A DermTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DermTech often face trade-offs trying to please all of them. DermTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DermTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bret Christensen | CEO President | Profile | |
| Kevin MBA | Treasurer CFO | Profile | |
| Burkhard MD | Chief Officer | Profile | |
| Todd Wood | Chief Officer | Profile | |
| Daniel Visage | Senior Access | Profile | |
| Steven Stone | Senior Development | Profile | |
| Loren MD | Chief Officer | Profile | |
| JD Esq | General Counsel | Profile | |
| Ray JD | G Counsel | Profile | |
| Jennifer Eilemberg | Chief Officer | Profile | |
| Ray Bassi | VP Sales | Profile | |
| John MD | CEO Pres | Profile | |
| William Zondler | Chief Officer | Profile | |
| Steve Kunszabo | Director Relations | Profile | |
| Michael Howell | Chief Officer | Profile | |
| Mark Aguillard | Chief Officer | Profile | |
| Claudia Ibarra | Chief Officer | Profile |
About DermTech Management Performance
The success or failure of an entity such as DermTech often depends on how effective the management is. DermTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DermTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DermTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (1.76) | (1.68) |
The data published in DermTech's official financial statements usually reflect DermTech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DermTech. For example, before you start analyzing numbers published by DermTech accountants, it's critical to develop an understanding of what DermTech's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of DermTech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DermTech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DermTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DermTech. Please utilize our Beneish M Score to check the likelihood of DermTech's management manipulating its earnings.
DermTech Workforce Analysis
Traditionally, organizations such as DermTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DermTech within its industry.DermTech Manpower Efficiency
Return on DermTech Manpower
| Revenue Per Employee | 74.3K | |
| Revenue Per Executive | 899.8K | |
| Net Loss Per Employee | 489.7K | |
| Net Loss Per Executive | 5.9M | |
| Working Capital Per Employee | 234.5K | |
| Working Capital Per Executive | 2.8M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for DermTech Stock analysis
When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.09) | Revenue Per Share 0.469 | Quarterly Revenue Growth 0.311 | Return On Assets (0.38) | Return On Equity (1.06) |
The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.